Skip to content
Peptigraph home

Is Ipamorelin Legal? FDA, Compounding and WADA Status

Ipamorelin's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGHRP (ghrelin receptor agonist)Updated
FDA status
Not approved
research chemical
PCAC vote
Not reviewed
not on the Jul 2026 PCAC agenda
WADA
Prohibited (S2.2.4)
In and out of competition
Not legal adviceStatus reflects public FDA and WADA records on the date shown. Rules differ by country and state.

Current status

Not FDA approved · research chemical

No. Ipamorelin is not FDA approved for any use.

Ipamorelin: regulatory status by country
CountryStatusSource
United StatesNo approved product foundNo FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "ipamorelin" returned no matches on 2 Oct 2026.api.fda.govchecked 2 Oct 2026

Timeline

  1. FDA warning letters to five research-peptide sellersEnforcement
Every peptide on the FDA tracker

Compounding and research-use sellers

  • Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
  • The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
  • "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.

FDA compounding record: Ipamorelin acetate is in FDA's 503B category 2 (added 29 September 2023). · fda.gov, checked 2 Oct 2026

Sport and drug testing

Prohibited by WADA (S2.2.4)

Ipamorelin is named as a growth hormone secretagogue in S2.2.4, prohibited at all times.

Outside the US

Rules differ by country. What each regulator's own records show, with the date we checked:

Ipamorelin: regulatory status by country
CountryStatusSource
United KingdomNo approved product foundNo approved product found in an emc (UK SmPC compendium) search for "ipamorelin" on 2 Oct 2026.medicines.org.ukchecked 2 Oct 2026
CanadaNo approved product foundNo product found in a Health Canada Drug Product Database search for ingredient "ipamorelin" on 2 Oct 2026.health-products.canada.cachecked 2 Oct 2026
AustraliaNo approved product foundNo approved product found in an ARTG search for "ipamorelin" on 2 Oct 2026.tga.gov.auchecked 2 Oct 2026
European UnionNo centrally authorised EU medicine foundEMA medicines list, searched 2 Oct 2026ema.europa.euchecked 2 Oct 2026

Ipamorelin is the one that stayed on the safety-risk list

FDA’s page lists Ipamorelin acetate in the main safety-risk table for outsourcing facilities (503B), added on September 29, 2023.[3]

The same page repeats the ipamorelin entry in its withdrawn-nominations table with the note that it also appears in the table above because it is in category 2 under the 503B interim policy.[3]

FDA's stated concern includes a literature report of serious adverse events including death when ipamorelin was given intravenously for gastric motility.[3]

Two further concerns appear in FDA's entry: compounded ipamorelin may trigger an immune response for certain routes because of aggregation or peptide-related impurities, and its unnatural amino acids make the peptide harder to characterise.[3]

What the April 2026 notice did not cover

The April notice concerned removals from Category 2 under the interim policy guidance; ipamorelin's listing is a separate entry described above.[9]

FDA's 503A Category 2 list, updated May 14, 2026, is a short list of other bulk drug substances (cesium chloride and domperidone among them).[10]

Sellers, blends and sport

An August FDA warning letter quoted a seller's marketing for a blend of tesamorelin and ipamorelin and listed that blend among unapproved new drugs.[11]

WADA names ipamorelin as an example of a growth hormone secretagogue in S2.2.4.[1]

The one randomized human trial in the evidence file gave intravenous ipamorelin infusions after bowel surgery.[12]

Common questions

Is ipamorelin FDA approved?

No. Drugs@FDA returns no match for ipamorelin.[2]

Is Ipamorelin legal to buy?

It is not an approved drug. Online sellers label it "for research use only, not for human use"; the FDA sent warning letters to five such sellers on 24 Aug 2026. Whether a pharmacy may compound it depends on its FDA bulk-substance status. Rules differ by country.

Is Ipamorelin banned by WADA?

Yes. Prohibited by WADA (S2.2.4), in and out of competition.

Ipamorelin FDA approval: what does FDA say about it?

FDA says it has not identified safety-related information for ipamorelin by certain other injectable routes, and so lacks sufficient information on whether those routes would harm humans.[3]

Is ipamorelin banned?

In sport, yes: WADA names it under growth hormone secretagogues.[1]

More on Ipamorelin

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "ipamorelin" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3US compounding: Ipamorelin acetate is in FDA's 503B category 2 (added 29 September 2023).U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  4. 4United Kingdom: No approved product found in an emc (UK SmPC compendium) search for "ipamorelin" on 2 Oct 2026.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
  5. 5Canada: No product found in a Health Canada Drug Product Database search for ingredient "ipamorelin" on 2 Oct 2026.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
  6. 6Australia: No approved product found in an ARTG search for "ipamorelin" on 2 Oct 2026.Therapeutic Goods Administration (Australia) · 2026tga.gov.auAccessed 2 Oct 2026
  7. 7EMA medicines export (centrally authorised medicines) (searched 2 Oct 2026)European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
  8. 8FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  9. 9Official web pageOfficial web page · web page
  10. 10Official web pageOfficial web page · web page
  11. 11Official web pageOfficial web page · web page
  12. 12Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026

Found an error? Report a correction.